DEUTSCHE BANK AG\
BankPosition in APGE — Apogee Therapeutics, Inc.
CIK 948046
FRANKFURT AM MAIN, 2M
Position in APGE
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$13,137,482
+$5,442,578 QoQ
Shares Held
98,979
+8.3% QoQ
Ownership
0.131%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#76
of 285 holders
Holding Since
Dec 2023
7 quarters on record
Voting authority
Sole 54%
Shared 0%
None 46%
Common Shares in APGE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026DEUTSCHE BANK AG\ holds $3,190,028,280 across 296 Biotechnology names. APGE ranks #32 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,579,110 | $784,391,303 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
518,409 | $323,248,743 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
815,400 | $245,459,858 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
888,019 | $166,308,196 | |
| 5 | RPRX |
Royalty Pharma plc
|
2,717,951 | $152,395,510 | |
| 6 | INCY |
Incyte Corp
|
1,262,988 | $143,172,312 | |
| 7 | ARGX |
Argenx SE
|
137,335 | $127,415,291 | |
| 8 | LGND |
Ligand Pharmaceuticals Inc
|
249,611 | $78,899,539 |
All Filings in APGE
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $13,137,482 | 98,979 | Shares | Defined | 2026-08-07 | |
| 2026-03-31 | $7,694,904 | 91,421 | Shares | Defined | 2026-05-06 | |
| 2025-12-31 | $5,990,168 | 79,361 | Shares | Defined | 2026-02-11 | |
| 2025-09-30 | $3,041,211 | 76,547 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $1,029,680 | 23,709 | Shares | Defined | 2025-08-12 | |
| 2025-03-31 | $1,078,545 | 28,869 | Shares | Defined | 2025-05-09 | |
| 2023-12-31 | $214,327 | 7,671 | Shares | Defined | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||